Education
About Us
Working with TipRanks
Follow Us
ASKA Pharmaceutical Holdings Co., Ltd. (JP:4886)
:4886
RESEARCH TOOLSreports
Total Valuation
ASKA Pharmaceutical Holdings Co., Ltd. has a market cap or net worth of ¥65.84B. The enterprise value is ¥31.69B.
Market Cap¥65.84B
Enterprise Value¥31.69B
Share Statistics
ASKA Pharmaceutical Holdings Co., Ltd. has 28,763,199 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding28,763,199
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
ASKA Pharmaceutical Holdings Co., Ltd.’s return on equity (ROE) is 0.08 and return on invested capital (ROIC) is 5.35%.
Return on Equity (ROE)0.08
Return on Assets (ROA)0.05
Return on Invested Capital (ROIC)5.35%
Return on Capital Employed (ROCE)0.07
Revenue Per Employee84.17M
Profits Per Employee6.69M
Employee Count762
Asset Turnover0.64
Inventory Turnover1.25
Valuation Ratios
The current PE Ratio of ASKA Pharmaceutical Holdings Co., Ltd. is 12.80. ASKA Pharmaceutical Holdings Co., Ltd.’s PEG ratio is -10.51.
PE Ratio12.80
PS Ratio0.00
PB Ratio0.62
Price to Fair Value1.00
Price to FCF12.89
Price to Operating Cash Flow10.02
PEG Ratio-10.51
Income Statement
In the last 12 months, ASKA Pharmaceutical Holdings Co., Ltd. had revenue of 64.14B and earned 5.10B in profits. Earnings per share was 179.94.
Revenue64.14B
Gross Profit31.34B
Operating Income5.33B
Pretax Income6.19B
Net Income5.10B
EBITDA8.49B
Earnings Per Share (EPS)179.94
Cash Flow
In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.
Operating Cash Flow0.00
Free Cash Flow0.00
Free Cash Flow per Share0.00
Dividends & Yields
ASKA Pharmaceutical Holdings Co., Ltd. pays an annual dividend of ¥25, resulting in a dividend yield of 2.04%
Dividend Per Share¥25
Dividend Yield2.04%
Payout Ratio27.79%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.59
52-Week Price Change1.07%
50-Day Moving Average2.34K
200-Day Moving Average2.16K
Relative Strength Index (RSI)65.83
Average Volume (3m)34.08K
Important Dates
ASKA Pharmaceutical Holdings Co., Ltd. upcoming earnings date is Aug 11, 2025, TBA (Confirmed).
Last Earnings DateMay 12, 2025
Next Earnings DateAug 11, 2025
Ex-Dividend DateMar 28, 2025
Financial Position
ASKA Pharmaceutical Holdings Co., Ltd. as a current ratio of 2.54, with Debt / Equity ratio of 23.15%
Current Ratio2.54
Quick Ratio1.39
Debt to Market Cap0.17
Net Debt to EBITDA0.04
Interest Coverage Ratio104.57
Taxes
In the past 12 months, ASKA Pharmaceutical Holdings Co., Ltd. has paid 1.09B in taxes.
Income Tax1.09B
Effective Tax Rate0.18
Enterprise Valuation
ASKA Pharmaceutical Holdings Co., Ltd. EV to EBITDA ratio is 7.73, with an EV/FCF ratio of -138.13.
EV to Sales1.02
EV to EBITDA7.73
EV to Free Cash Flow-138.13
EV to Operating Cash Flow26.40
Balance Sheet
ASKA Pharmaceutical Holdings Co., Ltd. has ¥10.17B in cash and marketable securities with ¥7.42B in debt, giving a net cash position of -¥2.74B billion.
Cash & Marketable Securities¥10.17B
Total Debt¥7.42B
Net Cash-¥2.74B
Net Cash Per Share-¥95.30
Tangible Book Value Per Share¥2.19K
Margins
Gross margin is 47.28%, with operating margin of 8.31%, and net profit margin of 7.95%.
Gross Margin47.28%
Operating Margin8.31%
Pretax Margin9.65%
Net Profit Margin7.95%
EBITDA Margin13.24%
EBIT Margin9.74%
Analyst Forecast
The average price target for ASKA Pharmaceutical Holdings Co., Ltd. is ¥2,600.00, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target¥2,600.00
Price Target Upside6.25% Upside
Analyst ConsensusHold
Analyst Count1
Revenue Growth Forecast2.06%
EPS Growth Forecast-32.48%